SA523440027B1 - عملية لتحضير مركبات أريل غير متجانس ثنائي وأشكال بلورية منها - Google Patents

عملية لتحضير مركبات أريل غير متجانس ثنائي وأشكال بلورية منها

Info

Publication number
SA523440027B1
SA523440027B1 SA523440027A SA523440027A SA523440027B1 SA 523440027 B1 SA523440027 B1 SA 523440027B1 SA 523440027 A SA523440027 A SA 523440027A SA 523440027 A SA523440027 A SA 523440027A SA 523440027 B1 SA523440027 B1 SA 523440027B1
Authority
SA
Saudi Arabia
Prior art keywords
certain
steps
biheteroaryl
elimination
need
Prior art date
Application number
SA523440027A
Other languages
Arabic (ar)
English (en)
Inventor
يوجو، جوناثان اوركيل،
مانول كونراث،
كاترين، مونيكا ميديرمان،
فابين هوفمان-ايمري،
ديان، اليزابث كاريرا،
كريستيان لاوتز،
Original Assignee
اف . هوفمان – لا روش ايه جى,
جينينتيك، إنك.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by اف . هوفمان – لا روش ايه جى,, جينينتيك، إنك. filed Critical اف . هوفمان – لا روش ايه جى,
Publication of SA523440027B1 publication Critical patent/SA523440027B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal Substances (AREA)
  • Steroid Compounds (AREA)
  • Catalysts (AREA)
SA523440027A 2020-10-02 2023-04-02 عملية لتحضير مركبات أريل غير متجانس ثنائي وأشكال بلورية منها SA523440027B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063087109P 2020-10-02 2020-10-02
PCT/US2021/053005 WO2022072721A1 (en) 2020-10-02 2021-09-30 Process for the preparation of biheteroaryl compounds and crystal forms thereof

Publications (1)

Publication Number Publication Date
SA523440027B1 true SA523440027B1 (ar) 2024-07-31

Family

ID=78599176

Family Applications (1)

Application Number Title Priority Date Filing Date
SA523440027A SA523440027B1 (ar) 2020-10-02 2023-04-02 عملية لتحضير مركبات أريل غير متجانس ثنائي وأشكال بلورية منها

Country Status (16)

Country Link
US (1) US20230312473A1 (enExample)
EP (1) EP4222154A1 (enExample)
JP (1) JP7805356B2 (enExample)
KR (1) KR20230079123A (enExample)
CN (1) CN116744933A (enExample)
AU (1) AU2021353532A1 (enExample)
BR (1) BR112023005853A2 (enExample)
CA (1) CA3200566A1 (enExample)
CL (3) CL2023000945A1 (enExample)
CR (1) CR20230183A (enExample)
IL (1) IL301266A (enExample)
MX (1) MX2023003759A (enExample)
PE (1) PE20230781A1 (enExample)
SA (1) SA523440027B1 (enExample)
WO (1) WO2022072721A1 (enExample)
ZA (1) ZA202303449B (enExample)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
EP0652775B1 (en) 1992-07-27 2000-04-19 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Targeting of liposomes to the blood-brain barrier
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
WO2002017930A2 (en) 2000-08-30 2002-03-07 The Board Of Trustees Of The Leland Stanford Junior University Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
AU2002322720B2 (en) 2001-07-25 2008-11-13 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
AU2003302676A1 (en) 2002-12-03 2004-06-23 Blanchette Rockefeller Neurosciences Institute Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
EP1663239A4 (en) 2003-09-10 2008-07-23 Cedars Sinai Medical Center KALIUM CHANNEL-MEDIATED FEEDING OF MEDICINES BY THE BLOOD BRAIN BARRIER
CN104043126A (zh) 2009-10-22 2014-09-17 霍夫曼-拉罗奇有限公司 轴突变性的调节
PE20161063A1 (es) * 2013-05-01 2016-10-22 Hoffmann La Roche Compuestos de biheteroarilo y usos de los mismos

Also Published As

Publication number Publication date
JP2023544037A (ja) 2023-10-19
US20230312473A1 (en) 2023-10-05
BR112023005853A2 (pt) 2023-05-02
ZA202303449B (en) 2025-04-30
WO2022072721A1 (en) 2022-04-07
AU2021353532A8 (en) 2023-05-04
CL2024003034A1 (es) 2025-02-21
IL301266A (en) 2023-05-01
JP7805356B2 (ja) 2026-01-23
CL2024003032A1 (es) 2025-02-21
CL2023000945A1 (es) 2023-09-29
PE20230781A1 (es) 2023-05-09
AU2021353532A1 (en) 2023-04-13
CA3200566A1 (en) 2022-04-07
EP4222154A1 (en) 2023-08-09
CR20230183A (es) 2023-06-14
MX2023003759A (es) 2023-04-24
CN116744933A (zh) 2023-09-12
KR20230079123A (ko) 2023-06-05

Similar Documents

Publication Publication Date Title
Murai et al. Asymmetric bromolactonization catalyzed by a C3-symmetric chiral trisimidazoline.
Yorimitsu et al. Radical Reaction by a Combination of Phosphinic Acid and a Base in Aqueous Media.
WO2006052688A3 (en) Catalyst and process for the metathesis of ethylene and butene to produce propylene
CN107530322B (zh) 斑螯素和生物活性斑螯素衍生物的商业上可行的合成
AU2002331372A1 (en) Catalyst and its use in the synthesis of hydrogen peroxide
ZA202303449B (en) Process for the preparation of biheteroaryl compounds and crystal forms thereof
EP1113001A3 (en) Process for producing nitrile compounds
CN109320516A (zh) 一种维奈妥拉中间体的制备方法及其产品
RU2689126C2 (ru) Способ получения 3-метил-2-нитробензойной кислоты посредством окисления воздухом
CN101100450A (zh) 乙磺酰基乙腈的制备方法
Molander et al. Organolanthanide catalyzed intramolecular 5-endo-dig hydroamination: An unusual anti-Markovnikov cyclization
Kraus et al. High yielding allylation of a chiral secondary alcohol containing base sensitive functional groups
CN111004198B (zh) 一种苯并吡喃衍生物的合成方法
Tokizane et al. Asymmetric reduction of racemic 2-isoxazolines
Matsuo et al. Silica-catalyzed carboxylative cyclization of propargylic amines with CO2
CN102391175B (zh) 2,2＇-联吡啶-4,4＇-二甲醛的绿色合成方法
CN114874187B (zh) 维他昔布的制备方法
Hashimoto et al. Catalytic process for efficient enantiodivergence of meso-N, N′-diacetyl-2-imidazolidinones and D LN-acetyl-2-oxazolidinones
UA87674C2 (ru) Способ получения нитрата бутоконазола
Chen et al. Synthetic Studies on d-Biotin, Part 9. An Improved Asymmetric Synthetic Route to d-Biotin via Hoffmann–Roche Lactone–Thiolactone Approach
EP1595862A4 (en) PROCESS FOR PRODUCING IODIC COMPOUNDS AND PROCESS FOR PRODUCING HIGH-PURITY 5-IODO-2-METHILBENZOIC ACID
CN115353497A (zh) 一种2-（2-苯并噻唑）取代乙醇醚类化合物的合成方法
CN102311381A (zh) 阿伐乙酯衍生物的合成方法
CN111978245A (zh) 一种3-氟-2-异丁基吡啶的制备方法
ZA200307704B (en) Method for preparing 7-quinolinyl-3,5-dihydroxyhept-6-enoate.